| scholarly article | Q13442814 |
| P2093 | author name string | Kazuhiko Nakagawa | |
| Toshiaki Takahashi | |||
| Hideyuki Harada | |||
| Yoichi Nakanishi | |||
| Makoto Nishio | |||
| Naruo Yoshimura | |||
| Nobuyuki Yamamoto | |||
| Takuyo Kozuka | |||
| Takeharu Yamanaka | |||
| Naonobu Kunitake | |||
| Tomonari Sasaki | |||
| Yukito Ichinose | |||
| Masaaki Kataoka | |||
| Takeshi Kodaira | |||
| Takashi Seto | |||
| Yasumasa Nishimura | |||
| Junichi Shimizu | |||
| Shinichi Tsutsumi | |||
| Hiromoto Kitajima | |||
| P2860 | cites work | Global cancer statistics, 2012 | Q27860501 |
| Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. | Q33344687 | ||
| The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer | Q33369465 | ||
| Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer | Q33385378 | ||
| S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). | Q33397978 | ||
| Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. | Q33399383 | ||
| Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study | Q33414372 | ||
| Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis | Q34298368 | ||
| S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial | Q35030387 | ||
| Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto | Q35568485 | ||
| Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats | Q41196248 | ||
| Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. | Q42972385 | ||
| Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. | Q43041920 | ||
| Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer | Q44957834 | ||
| Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer | Q45010015 | ||
| Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study | Q45056439 | ||
| PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q46202942 | ||
| Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial | Q46402909 | ||
| Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | Q47834638 | ||
| A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. | Q50454639 | ||
| Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. | Q53561280 | ||
| Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 | Q85546887 | ||
| Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer | Q86483382 | ||
| Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer | Q87492871 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 675-682 | |
| P577 | publication date | 2018-09-12 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L | |
| P478 | volume | 119 |
| Q64105066 | Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis |
| Q89535237 | S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501 |
| Q61447200 | S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials |
Search more.